Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. Latest Ratings for NKTR DateFirmActionFromTo Mar 2022OppenheimerUpgradesPerformOutperform Nov 2021BenchmarkUpgradesHoldBuy Nov 2021SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for NKTR View the Latest Analyst Ratings read more